VSTM Stock Recent News

VSTM LATEST HEADLINES

VSTM Stock News Image - businesswire.com

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that its management team is scheduled to participate and present at the following investor conferences in September: Cantor Global Healthcare Conference 2025: Fireside chat on Wednesday, September 3 at 3:55 pm ET H.C. Wainwright 27th Annual Global Investment Conference: Fireside chat on Monday, September 8.

businesswire.com 2025 Aug 27
VSTM Stock News Image - seekingalpha.com

Verastem, Inc. (NASDAQ:VSTM ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Daniel Calkins - Chief Financial Officer Daniel W. Paterson - President, CEO & Director Julissa Viana - Vice President of Corporate Communications & Investor Relations Matthew E.

seekingalpha.com 2025 Aug 08
VSTM Stock News Image - zacks.com

Verastem (VSTM) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.85. This compares to a loss of $0.31 per share a year ago.

zacks.com 2025 Aug 07
VSTM Stock News Image - zacks.com

Verastem (VSTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com 2025 Jul 31
VSTM Stock News Image - businesswire.com

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2025 financial results and business updates on Thursday, August 7, 2025, at 4:30 pm ET. To access the conference call, please dial (800) 715-9871 (U.S.) or (646) 307-1963 (international) and enter the passcode 1210516 at.

businesswire.com 2025 Jul 29
VSTM Stock News Image - seekingalpha.com

FDA approval of AVMAPKI FAKZYNJA CO-PACK marks a transformative milestone, positioning Verastem as a commercial-stage leader in KRAS-mutant LGSOC treatment. Verastem's strong cash position and promising pipeline, including VS-7375 for KRAS G12D, offer significant upside with multiple near-term catalysts ahead. Risks include slow commercial uptake, pipeline uncertainty, and potential future dilution, but current valuation under $5 presents an attractive entry point.

seekingalpha.com 2025 Jul 16
VSTM Stock News Image - businesswire.com

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the primary analysis of the Phase 2 RAMP 201 clinical trial was published online in the Journal of Clinical Oncology (JCO). The data reported in the publication showed that avutometinib plus defactinib demonstrated a confirmed overall response rate (ORR) of 31% in all patients with recurrent low-grade.

businesswire.com 2025 Jul 11
VSTM Stock News Image - businesswire.com

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of stock options to purchase 45,000 shares of its common stock to four new employees. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee's acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c).

businesswire.com 2025 Jul 08
VSTM Stock News Image - businesswire.com

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that updated results from the Phase 1/2 FRAME study conducted by The Institute of Cancer Research, London, and The Royal Marsden NHS Foundation Trust were published online in Nature Medicine. The full manuscript, titled “Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial,” w.

businesswire.com 2025 Jun 30
VSTM Stock News Image - seekingalpha.com

Recent pipeline updates highlight promising new product candidates advancing to late-stage trials, strengthening my confidence in future growth. The company maintains a solid financial position, with strong cash reserves and prudent expense management supporting ongoing R&D initiatives. Key strengths include a diversified portfolio and robust clinical data, though regulatory risks and competition remain notable challenges.

seekingalpha.com 2025 Jun 26
10 of 50